Atlas Venture Fund VI GmbH & Co KG
CIK 0001292358 Name as filed on the most recent filing
Filed as Atlas Venture Fund VI GmbH & Co KG (9)
50 transaction lines · from 9 filings · filed 2004-06-02 to 2012-03-06 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Horizon Pharma, Inc. 2 filings
- ISSUER Helicos Biosciences Corp 3 filings
- ISSUER Alnylam Pharmaceuticals, Inc. 3 filings
- ISSUER Momenta Pharmaceuticals Inc 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2012-03-02 |
Horizon Pharma, Inc. HZNP |
P, Open-market purchase | 828,443 acquired | 3.62 | 2,999,957.79 | Form 4, filing 0001104659-12-015909 | |
| 2011-08-02 |
Horizon Pharma, Inc. HZNP |
P, Open-market purchase | 352,576 acquired | 9.00 | 3,173,184.00 | Form 4, filing 0001209191-11-042498 | |
| 2011-08-02 |
Horizon Pharma, Inc. HZNP |
P, Open-market purchase | 10,782 acquired | 9.00 | 97,038.00 | Form 4, filing 0001209191-11-042498 | |
| 2011-08-02 |
Horizon Pharma, Inc. HZNP |
P, Open-market purchase | 6,456 acquired | 9.00 | 58,104.00 | Form 4, filing 0001209191-11-042498 | |
| 2009-09-18 |
Helicos Biosciences Corp HLCS |
P, Open-market purchase | 242,931 acquired | Not reported | Not priced | Form 4, filing 0001104659-09-055721 | |
| 2008-12-23 |
Helicos Biosciences Corp HLCS |
P, Open-market purchase | 8,620,690 acquired | Not reported | Not priced | Form 4, filing 0001179110-08-021567 | |
| 2007-05-30 |
Helicos Biosciences Corp HLCS |
P, Open-market purchase | 333,333 acquired | 9.00 | 2,999,997.00 | Form 4, filing 0001179110-07-011727 | |
| 2006-02-24 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 36,000 disposed | 14.80 | 532,692.00 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-24 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 34,439 disposed | 14.80 | 509,593.88 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-24 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 24,000 disposed | 14.80 | 355,128.00 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-24 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 18,971 disposed | 14.80 | 280,713.89 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-24 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 4,713 disposed | 14.80 | 69,738.26 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-24 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 930 disposed | 14.80 | 13,761.21 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-24 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 631 disposed | 14.80 | 9,336.91 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-24 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 316 disposed | 14.80 | 4,675.85 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-23 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 18,900 disposed | 15.14 | 286,176.24 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-23 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 18,081 disposed | 15.14 | 273,775.27 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-23 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 12,600 disposed | 15.14 | 190,784.16 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-23 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 9,960 disposed | 15.14 | 150,810.34 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-23 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 2,474 disposed | 15.14 | 37,460.32 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-23 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 488 disposed | 15.14 | 7,389.10 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-23 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 331 disposed | 15.14 | 5,011.87 | Form 4, filing 0001209191-06-013540 | |
| 2006-02-23 |
Alnylam Pharmaceuticals, Inc. ALNY |
S, Open-market sale | 166 disposed | 15.14 | 2,513.51 | Form 4, filing 0001209191-06-013540 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 73,201 acquired | 6.50 | 475,806.50 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 69,789 acquired | 6.50 | 453,628.50 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 48,799 acquired | 6.50 | 317,193.50 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 38,575 acquired | 6.50 | 250,737.50 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 4,791 acquired | 6.50 | 31,141.50 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 4,791 acquired | 6.50 | 31,141.50 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 2,134 acquired | 6.50 | 13,871.00 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 1,278 acquired | 6.50 | 8,307.00 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-21 |
Momenta Pharmaceuticals Inc MNTA |
P, Open-market purchase | 642 acquired | 6.50 | 4,173.00 | Form 4, filing 0001104659-04-017813 | |
| 2004-06-01 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 127,767 acquired | 6.00 | 766,602.00 | Form 4, filing 0001209191-04-029066 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 133,501 acquired | 6.00 | 801,006.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 8,739 acquired | 6.00 | 52,434.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 8,739 acquired | 6.00 | 52,434.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 1,170 acquired | 6.00 | 7,020.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 3,892 acquired | 6.00 | 23,352.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 2,331 acquired | 6.00 | 13,986.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 88,999 acquired | 6.00 | 533,994.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 70,351 acquired | 6.00 | 422,106.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 127,278 acquired | 6.00 | 763,668.00 | Form 4, filing 0001209191-04-030076 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 133,501 acquired | 6.00 | 801,006.00 | Form 4, filing 0001209191-04-029066 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 70,351 acquired | 6.00 | 422,106.00 | Form 4, filing 0001209191-04-029066 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 8,739 acquired | 6.00 | 52,434.00 | Form 4, filing 0001209191-04-029066 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 8,739 acquired | 6.00 | 52,434.00 | Form 4, filing 0001209191-04-029066 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 3,394 acquired | 6.00 | 20,364.00 | Form 4, filing 0001209191-04-029066 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 2,340 acquired | 6.00 | 14,040.00 | Form 4, filing 0001209191-04-029066 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 1,170 acquired | 6.00 | 7,020.00 | Form 4, filing 0001209191-04-029066 | |
| 2004-05-27 |
Alnylam Pharmaceuticals Inc ALNY |
P, Open-market purchase | 88,999 acquired | 6.00 | 533,994.00 | Form 4, filing 0001209191-04-029066 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Atlas Venture Fund VI GmbH & Co KG, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001292358
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6